These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12946321)

  • 1. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection.
    Luis Abad J; González MA; del Real G; Mira E; Mañes S; Serrano F; Bernad A
    Mol Ther; 2003 Sep; 8(3):475-84. PubMed ID: 12946321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
    Cagnon L; Rossi JJ
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
    Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
    J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
    Mohamed H; Gurrola T; Berman R; Collins M; Sariyer IK; Nonnemacher MR; Wigdahl B
    Front Immunol; 2021; 12():816515. PubMed ID: 35126374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.
    Lusso P; Vangelista L; Cimbro R; Secchi M; Sironi F; Longhi R; Faiella M; Maglio O; Pavone V
    FASEB J; 2011 Apr; 25(4):1230-43. PubMed ID: 21199933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
    Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
    Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes.
    Yang AG; Zhang X; Torti F; Chen SY
    Hum Gene Ther; 1998 Sep; 9(14):2005-18. PubMed ID: 9759928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
    Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
    Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of CCR5 antagonists as new therapies for HIV-1.
    Repik A; Richards KH; Clapham PR
    Curr Opin Investig Drugs; 2007 Feb; 8(2):130-9. PubMed ID: 17328229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1.
    Bouhlal H; Hocini H; Quillent-Grégoire C; Donkova V; Rose S; Amara A; Longhi R; Haeffner-Cavaillon N; Beretta A; Kaveri SV; Kazatchkine MD
    J Immunol; 2001 Jun; 166(12):7606-11. PubMed ID: 11390517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.
    Feng Y; Leavitt M; Tritz R; Duarte E; Kang D; Mamounas M; Gilles P; Wong-Staal F; Kennedy S; Merson J; Yu M; Barber JR
    Virology; 2000 Oct; 276(2):271-8. PubMed ID: 11040119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of coreceptor utilization to escape CCR5 antagonist therapy.
    Zhang J; Gao X; Martin J; Rosa B; Chen Z; Mitreva M; Henrich T; Kuritzkes D; Ratner L
    Virology; 2016 Jul; 494():198-214. PubMed ID: 27128349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.